Biom Pharmaceuticals announced today that the preclinical studies of antiviral preparation Bi121 showed significant antiviral activity against various strains of SARS-CoV-2.
(PRWeb February 03, 2022)
Read the full story at https://www.prweb.com/releases/biom_pharmaceuticals_antiviral_compound_bi121_shows_broad_spectrum_activity_against_three_variants_of_sars_cov_2/prweb18475667.htm
For more information, please visit
https://www.prweb.com/releases/biom_phar[...]f_sars_cov_2/prweb18475667.htm